Your browser doesn't support javascript.
loading
Cancer chemotherapy agents target intratumoral dendritic cells to potentiate antitumor immunity.
Müller, Philipp; Martin, Kea; Theurich, Sebastian; von Bergwelt-Baildon, Michael; Zippelius, Alfred.
Afiliação
  • Müller P; Cancer Immunology & Biology; Department of Biomedicine; University Hospital Basel and University of Basel ; Switzerland.
  • Martin K; Cancer Immunology & Biology; Department of Biomedicine; University Hospital Basel and University of Basel ; Switzerland.
  • Theurich S; Department I of Internal Medicine and Cologne Interventional Immunology; University Hospital Cologne ; Germany.
  • von Bergwelt-Baildon M; Department I of Internal Medicine and Cologne Interventional Immunology; University Hospital Cologne ; Germany.
  • Zippelius A; Cancer Immunology & Biology; Department of Biomedicine; University Hospital Basel and University of Basel ; Switzerland ; Department of Medical Oncology; University Hospital Basel ; Switzerland.
Oncoimmunology ; 3(8): e954460, 2014.
Article em En | MEDLINE | ID: mdl-25610745
ABSTRACT
Cytotoxic drugs capable of killing cancer cells in conjunction with targeted conversion of tumor resident, tolerogenic dendritic cells (DCs) into efficient antigen presenting cells (APCs) are highly complementary therapeutic routes to boost antitumor immunity. Our data suggest that the microtubule-depolymerizing compounds Dolastatin 10 and Ansamitocin P3 may serve as prototypes for a class of agents that display this binary mode of action.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2014 Tipo de documento: Article